Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated

Pacira BioSciences, Inc.

2026-Q1 EPS reported $0.07 revenue$177,376,000

Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).
GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.
Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.
Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.
Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $177.4 million, net income $2.9 million, or $0.07 per share (basic and diluted).

Period: the first quarter ended March 31, 2026
Revenue: $177.4 million
Net income: $2.9 million, or $0.07 per share (basic and diluted)
Result: reported results

Exact text from the filing

reference in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports First Quarter 2026 Financial Results -- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-028854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.